Smart Discharges for Older Children after Sepsis
Official title: Smart Discharges for Older Children: A Cohort Study to Develop Prognostic Algorithms for Post-discharge Readmission and Mortality Among Children Over 5 Years of Age
Run by University of British Columbia · NCT07629154 · Data updated 2026-11-12
This observational study follows children aged 5 to 16 who were treated for sepsis to see if a risk score built from their hospital stay can predict who might die or have poor health after going home.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 16 Years |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | University of British Columbia Academic / other |
| Locations | 7 sites (San Francisco, California and 6 other locations) |
| Status | Recruiting |
| Started | January 2, 2024 |
| Main results expected | April 2027 |
| Study ends | April 2027 |
| Registry record updated | June 15, 2026 |
| Trial ID | NCT07629154 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 5 to 16 years admitted with proven or suspected sepsis and whose guardians consent and provide contact information for follow-up.
✕Probably not a fit
Children without elevated post-discharge risk or those outside the catchment area or follow-up capabilities may see no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multinational, observational cohort study collects clinical and social data from children admitted with suspected or proven sepsis to develop and validate a risk-prediction model for post-discharge mortality in the 6 months after discharge. It also assesses health-related quality of life and functional status up to a year post-discharge. The study enrolls participants at admission and follows them for six months, aiming to create a scalable post-discharge support approach within resource-limited settings. No active intervention is given; the focus is on model development and outcome tracking to inform post-discharge care decisions. The work builds on prior Smart Discharges efforts and involves multiple institutions across high-income and low- to middle-income countries.
Why it matters
Potential benefit: If successful, the model could help clinicians and families identify high-risk children after discharge and tailor follow-up and resources to reduce mortality and improve quality of life.
How similar studies have gone: Previous Smart Discharges work has shown promise in predicting post-discharge risk in pediatric populations, supporting the potential for scale-up in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 0 and 16 years admitted to pediatric ward of hospital for proven or suspected infection * Provide informed consent * Ability to provide contact information (phone number or address) for phone or in-person follow-up Exclusion Criteria: * Child lives outside of the catchment area of a study site * Admitted for elective procedures, trauma, or short-term observation * Language barriers
Where it's running
-
The Rwanda Paediatric Association
Kigali, Rwanda Recruiting -
Catholic University Of Health And Allied Sciences
Mwanza, Tanzania Recruiting -
University of California, San Francisco
San Francisco, California, United States Not yet recruiting -
Weill Cornell Medicine
Ithaca, New York, United States Not yet recruiting -
University of Washington
Seattle, Washington, United States Not yet recruiting -
BC Children's Hospital Research Institute
Vancouver, British Columbia, Canada Active not recruiting
Show 1 more location
-
Walimu
Mbarara, Uganda Completed
Study contacts
- Study coordinator: Matthew Wiens, PhD
- Email: matthew.wiens@bcchr.ca
- Phone: 604-829-2562
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Early detection of sepsis-related blood clotting problems in severe burn patients
This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.
-
Neutrophil EMR3 as a biomarker for sepsis in ICU patients
Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.
-
Thymalfasin added to standard care for adults with sepsis and immune dysfunction
This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.
-
Multicenter group study of sepsis and ARDS in China
This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.